BlackfinBio

Blackfin Bio is an early-stage, private biotech company leveraging academic research from the University of Sheffield to build a pipeline of gene therapies targeting neurological diseases. The company's lead program has been de-risked through non-dilutive funding from LifeArc and seed investment from patient groups and angels. Currently in a pre-clinical or discovery stage, Blackfin is actively seeking further investment to advance its research and development efforts towards the clinic.

Next-generation gene therapy platform for CNS diseases, likely involving advanced viral vector design and delivery systems. Derived from University of Sheffield research.

The CNS gene therapy space is competitive, with numerous biotech firms and large pharma pursuing similar approaches. Blackfin's differentiation lies in its specific academic IP and focus on rare diseases as an initial proving ground.